1
|
Majumdar S, Mandal T, Mandal DD. Chitosan based micro and nano-particulate delivery systems for bacterial prodigiosin: Optimization and toxicity in animal model system. Int J Biol Macromol 2022; 222:2966-2976. [DOI: 10.1016/j.ijbiomac.2022.10.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Revised: 09/29/2022] [Accepted: 10/08/2022] [Indexed: 11/05/2022]
|
2
|
Majumdar S, Mandal T, Dasgupta Mandal D. Comparative performance evaluation of chitosan based polymeric microspheres and nanoparticles as delivery system for bacterial β-carotene derived from Planococcus sp. TRC1. Int J Biol Macromol 2022; 195:384-397. [PMID: 34863970 DOI: 10.1016/j.ijbiomac.2021.11.167] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 11/09/2021] [Accepted: 11/23/2021] [Indexed: 02/07/2023]
Abstract
β-carotene is a natural compound with immense healthcare benefits. To overcome insolubility and lack of stability which restricts its application, in this study, β-carotene from Planococcus sp. TRC1 was entrapped into formulations of chitosan‑sodium alginate microspheres (MF1, MF2 and MF3) and chitosan nanoparticles (NF1, NF2 and NF3). The maximum entrapment efficiency (%) and loading capacity (%) were 80.6 ± 4.28 and 26 ± 3.05 (MF2) and 92.1 ± 3.44 and 41.86 ± 4.65 (NF2) respectively. Korsmeyer-Peppas model showed best fit with release, revealing non-Fickian diffusion. Thermal and UV treatment exhibited higher activation energy (kJ/mol), 17.76 and 15.57 (MF2) and 37.03 and 19.33 (NF2) compared to free β-carotene (3.7 and 3.9), uncovering enhanced stability. MF2 and NF2 revealed swelling index (%) 721 ± 1.7 and 18.1 ± 1.5 (pH 6.8) and particle size 69.5 ± 3.2 μm and 92 ± 2.5 nm respectively. FESEM, FT-IR, XRD and DSC depicted spherical morphology, intactness of functional groups and masking of crystallinity. The IC50 (μg ml-1) values for antioxidant and anticancer (A-549) activities were 33.1 ± 1.7, 45.1 ± 2.8, 39.3 ± 2.9 and 31.3 ± 1.7, 27.9 ± 2.4, 25.3 ± 2.2 for β-carotene, MF2 and NF2 respectively with no significant cytotoxicity on HEK-293 cells and RBCs (p > 0.05). This comparative study of microspheres and nanoparticles may allow the diverse applications of an unconventional bacterial β-carotene with promising stability and efficacies.
Collapse
Affiliation(s)
- Subhasree Majumdar
- Department of Biotechnology, National Institute of Technology, Mahatma Gandhi Avenue, Durgapur 713209, West Bengal, India; Department of Zoology, Sonamukhi College, Sonamukhi, Bankura 722207, West Bengal, India
| | - Tamal Mandal
- Department of Chemical Engineering, National Institute of Technology, Mahatma Gandhi Avenue, Durgapur 713209, West Bengal, India
| | - Dalia Dasgupta Mandal
- Department of Biotechnology, National Institute of Technology, Mahatma Gandhi Avenue, Durgapur 713209, West Bengal, India.
| |
Collapse
|
3
|
Magalhães APDSPA, Toma HK, do Carmo FA, Mansur CRE. Development of purified cashew gum mucoadhesive buccal tablets containing nystatin for treatment of oral candidiasis. Drug Dev Ind Pharm 2021; 47:825-837. [PMID: 34033502 DOI: 10.1080/03639045.2021.1934868] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
OBJECTIVE The objective of this work was to prepare mucoadhesive buccal tablets containing nystatin and purified cashew gum for the treatment of oral candidiasis. SIGNIFICANCE Mucoadhesive buccal tablets containing the drug nystatin are an alternative to oral suspensions, which cause low therapeutic adherence to the treatment of oral candidiasis. Purified cashew gum has been studied as a diluent and mucoadhesive agent in tablets. METHODS Two batches of mucoadhesive tablets were produced, MT1 and MT 2, containing purified cashew gum, nystatin (500,000 IU), flavoring agent and with or without the presence of lubricant agent. The average weight, mechanical properties, dose uniformity, drug release profile, mucoadhesive properties and antimicrobial activity against Candida albicans were evaluated. RESULTS Tablets presented average weight of 329.1 ± 3.1 mg (MT1) and 334.6 ± 1.5 mg (MT2), hardness of 9.8 ± 0.8 KgF (MT1) and 8.3 ± 0.4 KgF (MT2), friability of 0.2% (MT1 and MT2), and dose uniformity of 102.20 ± 1.17% (MT1) and 99.06 ± 7.40% (MT2). MT1 and MT2 were able to swell, erode, release the drug and remain adhered to the pig's cheek up to 3 h for batch MT1 and 4 h for batch MT2, and the amount of nystatin released since the beginning of the test in both batches was sufficient to inhibit the growth of the fungus. CONCLUSIONS Therefore, the proposed formulation proved to be very promising and met all the studied criteria, showing to be ideal for the treatment of oral candidiasis.
Collapse
Affiliation(s)
| | - Helena Keiko Toma
- Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | | | - Claudia Regina Elias Mansur
- Institute of Macromolecules, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.,Program of Materials Engineering and Metallurgy, Technology Center, Alberto Luiz Institute of Coimbra, Post-Graduation and Engineering Research - COPPE, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| |
Collapse
|
4
|
de Moura Ferraz LR, Tabosa AÉGA, da Silva Nascimento DDS, Ferreira AS, Silva JYR, Junior SA, Rolim LA, Rolim-Neto PJ. Benznidazole in vitro dissolution release from a pH-sensitive drug delivery system using Zif-8 as a carrier. JOURNAL OF MATERIALS SCIENCE. MATERIALS IN MEDICINE 2021; 32:59. [PMID: 33999312 PMCID: PMC8128829 DOI: 10.1007/s10856-021-06530-w] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Accepted: 04/20/2021] [Indexed: 06/12/2023]
Abstract
Chagas disease is a neglected tropical disease caused by the flagellate protozoan Trypanosoma cruzi (T. cruzi). Endemic in underdeveloped and developed countries, due to the migratory movement, it is considered a serious public health problem. Endemic in underdeveloped countries and due to the migratory movement, in developed countries as well, it is considered a serious public health problem. One of the reasons for this is a weak therapeutic arsenal, represented only by the drug benznidazole (BNZ) which, although it promotes significant cure rates in the acute phase of the disease, presents serious problems of toxicity and bioavailability, mainly due to its low aqueous solubility. Several studies have presented several drug delivery systems (DDS) based on BNZ aiming at enhancing its solubility in aqueous medium and, with this, promoting an increase in the dissolution rate and, consequently, in its bioavailability. However, the present work is a pioneer in using a zeolitic imidazolate framework as a carrier agent for a DDS in order to promote a pH-sensitive modulation of the drug. Thus, this work aimed to develop a novel DDS based on BNZ and the ZIF-8 to use it in development of prolonged-release dosage forms to alternative treatment of Chagas disease. The BNZ@ZIF-8 system was obtained through an ex situ method selected due to its higher incorporation efficiency (38%). Different characterization techniques corroborated the obtainment and drug release data were analyzed by in vitro dissolution assay under sink and non-sink conditions and setting the kinetic results through both model dependent and independent methods. Under sink conditions, at pH 4.5, BNZ and BNZ@ZIF-8 showed similar release profile, but the DDS was effective in promoting a prolonged release. At pH 7.6, after 7 h, BNZ showed a lower release than BNZ@ZIF-8. On the other hand, in non-sink conditions at pH 4.5 the BNZ presented 80% of drug release in 3 h, while the DDS in 6 h. At pH 7.6, BNZ presented a release of 80% in 2 h, while the DDS reaches it in only at 12 h. Therefore, at pH 4.5 the DDS BNZ@ZIF-8 showed a faster release with a burst effect, while at pH 7.6 it showed a prolonged and controlled release. Finally, it is evident that a promising DDS pH-sensitive was obtained as a novel carrier that might be able to prolongs BNZ release in dosage forms intended for the alternative treatment of Chagas disease.
Collapse
Affiliation(s)
- Leslie Raphael de Moura Ferraz
- Laboratório de Tecnologia dos Medicamentos (LTM), Department of Pharmaceutical Sciences, Federal University of Pernambuco, Av. Prof. Arthur de Sá, s/n, Cidade Universitária, 50740-521, Recife, PE, Brazil.
| | - Alinne Élida Gonçalves Alves Tabosa
- Laboratório de Tecnologia dos Medicamentos (LTM), Department of Pharmaceutical Sciences, Federal University of Pernambuco, Av. Prof. Arthur de Sá, s/n, Cidade Universitária, 50740-521, Recife, PE, Brazil
| | - Débora Dolores Souza da Silva Nascimento
- Laboratório de Tecnologia dos Medicamentos (LTM), Department of Pharmaceutical Sciences, Federal University of Pernambuco, Av. Prof. Arthur de Sá, s/n, Cidade Universitária, 50740-521, Recife, PE, Brazil
| | - Aline Silva Ferreira
- Laboratório de Tecnologia dos Medicamentos (LTM), Department of Pharmaceutical Sciences, Federal University of Pernambuco, Av. Prof. Arthur de Sá, s/n, Cidade Universitária, 50740-521, Recife, PE, Brazil
| | - José Yago Rodrigues Silva
- Laboratório de Terras Raras (BSTR), Fundamental Departament of Chemistry, Federal University of Pernambuco, Av. Jornalista Aníbal Fernandes, s/n - Cidade Universitária, 50740-560, Recife, PE, Brazil
| | - Severino Alves Junior
- Laboratório de Terras Raras (BSTR), Fundamental Departament of Chemistry, Federal University of Pernambuco, Av. Jornalista Aníbal Fernandes, s/n - Cidade Universitária, 50740-560, Recife, PE, Brazil
| | - Larissa Araújo Rolim
- Central Analítica de Fármaco, Medicamentos e Alimentos (CAFMA), Federal University of Vale do São Francisco, Av. José de Sá Maniçoba, s/n, Centro, 56304-917, Petrolina, PE, Brazil
| | - Pedro Jose Rolim-Neto
- Laboratório de Tecnologia dos Medicamentos (LTM), Department of Pharmaceutical Sciences, Federal University of Pernambuco, Av. Prof. Arthur de Sá, s/n, Cidade Universitária, 50740-521, Recife, PE, Brazil
| |
Collapse
|
9
|
Barkat K, Ahmad M, Minhas MU, Khalid I. Oxaliplatin-loaded crosslinked polymeric network of chondroitin sulfate-co
-poly(methacrylic acid) for colorectal cancer: Its toxicological evaluation. J Appl Polym Sci 2017. [DOI: 10.1002/app.45312] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Kashif Barkat
- Faculty of Pharmacy and Alternative Medicine; Islamia University of Bahawalpur; Punjab 63100 Pakistan
| | - Mahmood Ahmad
- Faculty of Pharmacy and Alternative Medicine; Islamia University of Bahawalpur; Punjab 63100 Pakistan
| | - Muhammad Usman Minhas
- Faculty of Pharmacy and Alternative Medicine; Islamia University of Bahawalpur; Punjab 63100 Pakistan
| | - Ikrima Khalid
- Faculty of Pharmacy and Alternative Medicine; Islamia University of Bahawalpur; Punjab 63100 Pakistan
| |
Collapse
|
10
|
Biocompatible hyperbranched polyglycerol modified β-cyclodextrin derivatives for docetaxel delivery. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2016; 71:965-972. [PMID: 27987795 DOI: 10.1016/j.msec.2016.11.005] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2016] [Revised: 10/19/2016] [Accepted: 11/02/2016] [Indexed: 01/24/2023]
Abstract
The development of biocompatible vector for hydrophobic drug delivery remains a longstanding issue in cancer therapy. We design and synthesis a drug delivery system based on HPG modified β-CD (β-CD-HPG) by conjugating HPG branches onto β-CD core and its structure was confirmed by NMR, FTIR, GPC and solubility. In vitro biocompatibility tests showed that HPG modification significantly improved red blood cells morphology alteration and hemolysis cause by β-CD and β-CD-HPG displayed cell safety apparently in a wide range of 0.01-1mg/mL. An anti-cancer drug, docetaxel, was effectively encapsulated into β-CD-HPG which was confirmed by DSC analysis. This copolymer could form nanoparticles with small size (<200nm) and exhibited better DTX loading capacity and controlled release kinetics without initial burst release behavior compared with β-CD. Furthermore, antitumor assay in vitro show that β-CD-HPG/DTX effectively inhibited proliferation of human breast adenocarcinoma cells. Therefore, β-CD-HPG/DTX exhibit great potential for cancer chemotherapy.
Collapse
|